Thematic hub | Healthcare | Pharmaceuticals

What is the pharmaceutical sector?

Pharmaceuticals stocks form a subsector of the broader healthcare group, and include businesses involved in the research, development, manufacturing, and distribution of drugs, including prescription medicines and other medical treatments.

With ADSS, customers can invest in pharmaceutical stocks with zero commission.

Open account

The largest pharmaceutical companies develop new drugs to add to their existing portfolio, while smaller, research-focused pharma stocks target specific areas to develop new medicines. Other companies produce generic versions of prescription drugs that are no longer under patent. Outside of drug development and manufacturing, this diverse sector also includes companies developing specialised drug delivery systems or related products, with a variety of different investment characteristics. Healthcare is generally a defensive sector, since demand for medicines is stable across the business cycle, but research-intensive pharma stocks are an exception. These companies have speculative business models and share some of their price characteristics with tech companies, being more volatile than the general market, with the potential for high returns, typically uncorrelated with overall economic growth.

What are thematic stocks? Discover stock sectors and investment themes with ADSS here

Development cycles and pharma investments

Pharmaceuticals companies involved in drug discovery make long-term investments, with many individual drug candidates investigated for each successful, approved patent. Drug development timelines can span decades from the initial research to market launch, with regulatory approval processes creating significant uncertainty around revenue. In the US, the FDA approval pathway requires multiple phases of clinical trials, each with substantial costs and risk of failure, making drug development one of the most capital-intensive and uncertain business activities across all stock sectors. Extremely high profits for successful new drugs recuperate the cost of failed candidates, and US patent law allows a 20-year period where only the drug developer is permitted to produce the drug as a branded version. After this, rival companies may produce cheaper, generic versions of the same drug, typically causing a sharp drop in sales. This arrangement makes pharma stocks unique amongst research-intensive, speculative sectors such as information technology or high-tech manufacturing in terms of their dependence on regulators to ensure profitability.

Drug pipelines and drug portfolios

There are various stages a drug must pass through before it can be approved for use by humans. At each stage, a large portion of candidate molecules are abandoned, with those in late-stage trials more likely to reach the market. This means drug stocks with strong pipelines of drugs in late-stage clinical trials trade at premiums to reflect potential future revenues. Because of their extensive drug portfolios, established names like Pfizer offer greater revenue stability and so exhibit more stable share prices, with some defensive characteristics such as regular dividends, typical of the consumer staples sector.

Sector Highlights

Global market size: The size of the global pharmaceutical market reached $1.7 trillion in 2024, and the drug manufacturers stock sector has a market capitalisation of over $2.1 trillion.
Top stocks: Johnson & Johnson, Eli Lilly, Pfizer
Important themes: Regulation, drug pricing, AI

Browse all sectors

Learn more about stocks, stock trading, and financial markets with ADSS Education.

Important pharma stocks

Pricing from TradingView is indicative and does not represent ADSS pricing.

Open an account and start investing with ADSS today

Open account

Market trends impacting pharmaceuticals stocks

The business model of the pharmaceutical sector relies on the split between patent and generic drugs, with the former commanding large premiums and allowing drug developers to recuperate the cost of discovery. In the US as in many markets, drug companies are under pressure over the profit margins charged on new drugs, which in some cases are exceedingly high. ‘Blockbuster drugs’, which generate over $1 billion in revenue, are critical for the financial viability of pharma stocks but in some cases, as in arthritis-drug Humira, returns on a single product are in the hundreds of billions. This has caused public pressure to restrict drug pricing, which will impact the bottom line for major pharma stocks, especially more specialised drug development firms without a large portfolio of approved drugs.

Get started with
ADSS today

Opening an account with ADSS in 3 easy steps.

Start investing

Register

Submit online application (UAE residents can apply with UAE Pass)

Fund

Fund using Mastercard, VISA, UAEPGS (for UAE bank accounts holders only)

Invest

Invest in pharmaceuticals stocks through the ADSS platform

FAQs

What makes pharma stocks different from other healthcare investments?

Pharma stocks represent a unique subsector within healthcare that focuses specifically on drug discovery, drug development, and pharmaceutical manufacturing. Unlike broader healthcare companies, pharmaceutical sector investments are characterised by extremely long development cycles, with drug development timelines spanning decades from initial research to market launch. These drug companies operate under a unique business model where successful blockbuster drugs must generate enough revenue to offset the substantial costs of failed drug candidates. The pharmaceutical sector’s dependence on regulatory approval and patent protection makes these investments more speculative and volatile than traditional defensive healthcare stocks, sharing characteristics with technology companies despite being part of the generally stable healthcare industry.

How do drug patents affect pharmaceutical stocks’ performance?

Drug patents are fundamental to the profitability of pharmaceutical stocks, and provide a 20-year period of market exclusivity for successful drug discoveries. During this patent protection period, only the original drug developer can manufacture and sell the branded version, allowing them to charge premium prices that recuperate the massive costs of drug discovery and development. However, once patents expire, generic drug manufacturers can produce cheaper alternatives, typically causing sharp declines in sales for the original pharmaceutical companies. This patent cliff effect means that drug stocks with strong pipelines of late-stage clinical trials trade at premiums, as investors anticipate future revenue streams from new patent-protected medicines entering the market.

What are the main risks when investing in drug development companies?

All investments involve risk, but investing in pharmaceutical companies involves several unique dangers because of the uncertain nature of drug development. The failure of an individual drug candidate can cause a significant financial blow. Regulatory pressure on drug pricing, particularly for blockbuster drugs generating over $1 billion in revenue, also poses a threat to profit margins. Smaller, research-focused pharmaceutical stocks are especially vulnerable as they lack diversified drug portfolios to cushion against individual product failures, whilst even established drug manufacturers face revenue volatility when key patents expire and generic competition emerges.